Emerging evidence highlights PAR2 as a promising therapeutic target in atopic dermatitis, due to its pivotal role in skin barrier impairment, inflammatory cytokine release, and type 2 immune responses [15,17]. This evidence concerns the gene F2RL1 and atopic eczema.